I was diagnosed with stage IV lung cancer in 2012. I knew my time was limited, and that I faced an uncertain future. But almost 5 years later, I find myself in a place I never expected to be---against 50:1 odds and tumors in my spine, lymphatic system, brain, and lungs---I\'m alive.

To my surprise, I also remain hopeful. Not a hope that everything will be fine. Not a hope that my cancer will be cured. But more a hope that enough things will continue to go my way so I\'m free to focus my attention not on cancer, but on the joy each new day brings.

I am still afraid of the inevitable path this disease most likely will travel, but I aim to strike an acceptable balance between hope and fear in the same way I\'ve approached most of the challenges in my life. I step back and I assume everything makes sense. In my past, I worked in the tech industry and felt the excitement of discovery and the thrill of success, even against very difficult odds. The thrill is contagious, and in some sense, it showed me how a group of people, by joining together, can slay any dragon.

Using reason and logic, I seek out my personal definition of hope, one that avoids having too much optimism or pessimism vis‐à‐vis my current reality. This helps me determine which concerns deserve my attention and which ones are beyond my control and I choose to ignore, at least for the time being.

Along with this, I have learned about cancer---about biology and about drug development. I have read research and learned about genetics by auditing a college‐level course and watching NIH NHGRI videos. I have interviewed scientists involved in the drug development process and others involved in basic academic research. I have listened and learned from my wife, a lifelong teacher in the Department of Physiology and Neurobiology at the University of Connecticut.

I have developed an informed expectation, as much as is possible, of what new treatments are available or are likely to be available in the near future. It hinges on important aspects of my cancer experience---a doctor who sees me as her partner, sharing extensive information about ongoing and future drug trials for which I might be a candidate; a hospital that provides access to the latest clinical drug trials; and health insurance, which thus far has covered my many treatments. I hope that all in my situation are as fortunate, though I know many are not.

What have I learned? I learned that biology, genetics, and drug development are far, far more complex than any of the computers and software that were the basis for my professional career. I learned that 10 years ago, trial and error and luck all played very significant roles in drug development process. The tools available at the time helped, but did not quickly or accurately determine the molecular structures of proteins, which themselves are complex and exist in an even more complex environment. All of which made understanding the mechanisms and pathways associated with processes within cells incredibly difficult to do. Fast forward to the present---I learned that drug development involves even larger teams than just 10 years ago. These teams are staffed with specialized, very highly skilled scientists who utilize the latest advances in technology working alongside clinician researchers, statisticians, and clinical staff. I now know "things are getting better." But we aren\'t there yet: drug development continues to be science based on significant components of trial, error, and luck. All in all, my education reminded me that I\'m not alone; there\'s an amazing team intensely working to help me and all patients with cancer.

With this knowledge, I find I am now better prepared to manage my experiences. I can accept that drugs are effective, but only for a while. I realize that all treatments have side effects, even the best ones. I also know how amazingly fast the disease can progress when a drug stops working. And, most frightening, I have firsthand knowledge of how disease progression feels, and how very much I don\'t like those feelings.

Where does this leave me now? What plan should I have? To answer, I begin with a simple question: How far out does my new plan have to carry me? For me, a one‐day plan is unacceptable, but planning for a year seems beyond my reality, perhaps even "falsely optimistic." I have learned (firsthand) that patients with cancer get by because of two factors. The first and most significant is pure luck---luck that your cancer has a mutation causing it to grow and that there is a drug that can prevent that mutation from wreaking havoc. The second, though, is how well we deal with uncertainty. We grow up learning that physicians "always have the answer." Today in cancer, as it has been for many years, most answers remain hidden. So we take our treatments and hear constant reminders in the media about the great progress in targeted medicine. In this case, reality for most of us doesn\'t quite match the hype.

Therefore, I decide a plan that lasts a few months would be comfortable. With that horizon, I can avoid the uncertainties of the long term and need not reconsider it until something changes. More importantly, it allows me to shelve many of the hard questions I prefer not to face, at least for a while. I believe my next iteration of my plan has to be based on the hope of some new, yet to be discovered, treatment regimen about which I, and even the researchers, have no information yet.

Or, said another way, my plan trades the usually disappointing certainty of past treatment methods for the uncertainty of the possible discovery of a much better treatment. Not a situation someone with a need for immediate answers would find very reassuring, but for some of us, it\'s a better deal than we had expected.

Maybe this isn\'t a perfect or the best plan, but *I don\'t have the time* to keep working at this. There is too much joy living each day to be distracted by something that can\'t be predicted ... something way out in the future.
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